The purpose of this training program is to prepare postdoctoral researchers for careers in immunologic research that will enable them to have a significant impact on the prevention, diagnosis and treatment of cancer. Over the past decade the field of immunology has witnessed an unprecedented level of discovery on every front. These exciting advances have led to an improved understanding of how cancers evade the immune system and how innate and specific immunity can be manipulated to generate an anti-tumor immune response. In order to translate this new knowledge into effective treatments for cancer, it will be necessary to train a new generation of immunologists who are well-versed in the most recent concepts in immunology. Trainees will engage in an intensive program of immunologic research under the guidance of an accomplished mentor with expertise in a specific area of immunology. This will permit the young investigator to develop a focused immunologic research question and relate it to important clinical and scientific problems. In order that they have thorough exposure to the principles underlying the conduct of immunologic research, trainees will participate in a carefully designed program of courses, conferences, and meetings sponsored by the Ohio State University Comprehensive Cancer Center (OSUCCC) and the Immunology Program. Trainees will also benefit from significant exposure to related disciplines such as bioinformatics, biostatistics, human cancer genetics, translational medicine, and experimental therapeutics, as well as training in grant writing and the responsible conduct of research. Trainees will be introduced to state of the art methodologies and scientific techniques. This program will encourage the participation of both physician-scientists and trainees with a basic science background in order to enhance the exchange of ideas, stimulate intellectual curiosity, and broaden the perspectives of the participants. There has been and will continue to be a concerted effort to recruit persons from under-represented groups into this program. Successful completion of this inter-disciplinary training program will foster the development of the trainee's scientific research skills in preparation for an immunologic research career that will have a positive impact on the health needs of our nation's cancer patients. Indeed, all 13 former trainees have continued with academic pursuits and all have maintained the expected career trajectory. Twelve of these former trainees are still involved in tumor immunology research. Four of the more senior alumni have successfully competed for peer-reviewed K level funding and one has received an American Cancer Society Post-Doctoral Fellowship Award. Since the last renewal, four trainees from under-represented groups were recruited to this training program.
The purpose of this training program is to prepare post-doctoral researchers for careers in immunologic research so that they can have a significant impact on the prevention, diagnosis and treatment of cancer. Successful completion of this will foster the development of the trainee's scientific research skills in preparation for an immunologic research career that will have a positive impact on the health needs of our nation's cancer patients.
|Willis, William L; Wang, Linan; Wada, Takuma Tsuzuki et al. (2018) The proinflammatory protein HMGB1 is a substrate of transglutaminase-2 and forms high-molecular weight complexes with autoantigens. J Biol Chem 293:8394-8409|
|Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368|
|Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509|
|Pyter, Leah M; Suarez-Kelly, Lorena P; Carson 3rd, William E et al. (2017) Novel rodent model of breast cancer survival with persistent anxiety-like behavior and inflammation. Behav Brain Res 330:108-117|
|Suarez-Kelly, Lorena P; Campbell, Amanda R; Rampersaud, Isaac V et al. (2017) Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy. Nanomedicine 13:909-920|
|Latchana, Nicholas; Abrams, Zachary B; Howard, J Harrison et al. (2017) Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. Bioinform Biol Insights 11:1177932217694837|
|Farren, Matthew R; Hennessey, Rebecca C; Shakya, Reena et al. (2017) The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther 16:417-427|
|Talbert, Erin E; Yang, Jennifer; Mace, Thomas A et al. (2017) Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Mol Cancer Ther 16:344-356|
|Yang, Jennifer; Farren, Matthew R; Ahn, Daniel et al. (2017) Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opin Ther Targets 21:485-498|
|Markowitz, Joseph; Wang, Jiang; Vangundy, Zach et al. (2017) Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Sci Rep 7:15424|
Showing the most recent 10 out of 70 publications